BioStar Capital

Nectero Medical is a clinical-stage biotechnology company based in Dover, Delaware, that focuses on treating mid-sized abdominal aortic aneurysms. Founded in 2017, the company has developed an innovative treatment designed to stabilize the growth of aneurysms and prevent their rupture. This treatment delivers a compound containing a stabilizer agent directly to the aneurysm site, which helps inhibit further breakdown and strengthens the vessel wall. By providing a safer intervention option, Nectero Medical aims to enable patients to receive timely care, significantly delaying or preventing the need for major endovascular or surgical repair.

We believe that all patients deserve the most innovative, open surgical treatment options so they can live their fullest lives. We’re on a mission to advance robotic technology that pushes the limits of soft tissue open surgery and opens new opportunities for surgeons to restore quality of life for more patients with complex conditions. The Symani® Surgical System is a first-of-its kind robotic technology that uniquely addresses the scale and complexities of microsurgery and supermicrosurgery to restore quality of life for more patients.

Amplitude Vascular Systems is a medical device company focused on safely and effectively treating severely calcified arterial disease. It was founded in 2020 and is based in Ann Arbor, Michigan.

Amplitude Vascular Systems is a medical device company focused on safely and effectively treating severely calcified arterial disease. It was founded in 2020 and is based in Ann Arbor, Michigan.

Amplitude Vascular Systems is a medical device company focused on safely and effectively treating severely calcified arterial disease. It was founded in 2020 and is based in Ann Arbor, Michigan.

REVA Medical, Inc. is a medical device company specializing in the development and commercialization of polymer-based bioresorbable products for vascular applications. The company focuses on innovative solutions for coronary artery disease and peripheral artery disease, offering its lead products: the Fantom Encore, a bioresorbable vascular scaffold for coronary artery treatment, and the MOTIV scaffold for below-the-knee applications. These products are designed to support the artery during the healing process and subsequently dissolve, restoring natural artery function. REVA Medical markets its Fantom Encore product in several European countries, including Germany, Austria, and Italy. Founded in 1998 and headquartered in San Diego, California, REVA Medical aims to improve patient health through the use of advanced biomaterials in implantable medical devices.

We believe that all patients deserve the most innovative, open surgical treatment options so they can live their fullest lives. We’re on a mission to advance robotic technology that pushes the limits of soft tissue open surgery and opens new opportunities for surgeons to restore quality of life for more patients with complex conditions. The Symani® Surgical System is a first-of-its kind robotic technology that uniquely addresses the scale and complexities of microsurgery and supermicrosurgery to restore quality of life for more patients.

Ablative Solutions, Inc. is a clinical-stage medical device company focused on developing innovative treatments for hypertension. Incorporated in 2011 and headquartered in San Jose, California, with an additional office in Kalamazoo, Michigan, the company manufactures the Peregrine System, an endovascular catheter designed for the minimally invasive delivery of diagnostic and therapeutic agents into the perivascular space surrounding peripheral blood vessels. This technology provides a safe and effective alternative to traditional surgical renal denervation, aiming to reduce blood pressure in patients with hypertension that is not well controlled. By using alcohol as a neurolytic agent, Ablative Solutions' infusion catheter may offer significant advantages over energy-based systems, making it a promising option for managing hypertension and related conditions caused by an overactive sympathetic nervous system.

Aria CV, Inc. is a medical device company based in St. Paul, Minnesota, founded in 2010 by Drs. John Scandurra and Karl Vollmers. The company specializes in developing an implantable cardiovascular device aimed at treating pulmonary arterial hypertension (PAH). This innovative device is designed to reduce the workload on the right side of the heart, potentially enhancing both survival rates and the quality of life for patients suffering from this condition. Aria CV holds an exclusive license for certain patents from the University of Minnesota, reflecting its strong ties to academic research and innovation in the field of medical devices.

Corindus designs, manufactures, and commercializes remote robotic systems for interventional procedures. The company's products include CorPath, which enables physicians to perform catheterization procedures from a remote location away from the radiation zone. The company was formerly known as Navicath, Ltd. Corindus was founded in 2002 and is based in Waltham, Massachusetts.

Trice Medical, Inc. is a company that specializes in developing orthopedic diagnostic devices incorporating camera-enabled and needle-based technologies. Founded in 2011 and based in Malvern, Pennsylvania, Trice Medical aims to enhance orthopedic diagnostics for patients, physicians, and payors by providing immediate, clear answers through its innovative solutions. By enabling micro-invasive procedures that are painless and cosmetically undetectable, the company's products facilitate office-based diagnostic and therapeutic applications. Trice Medical's technology integrates miniaturized optoelectronics, optimizing clinical services and addressing the shortcomings of traditional diagnostic modalities, thereby reducing false readings and overall healthcare costs.

Ablative Solutions, Inc. is a clinical-stage medical device company focused on developing innovative treatments for hypertension. Incorporated in 2011 and headquartered in San Jose, California, with an additional office in Kalamazoo, Michigan, the company manufactures the Peregrine System, an endovascular catheter designed for the minimally invasive delivery of diagnostic and therapeutic agents into the perivascular space surrounding peripheral blood vessels. This technology provides a safe and effective alternative to traditional surgical renal denervation, aiming to reduce blood pressure in patients with hypertension that is not well controlled. By using alcohol as a neurolytic agent, Ablative Solutions' infusion catheter may offer significant advantages over energy-based systems, making it a promising option for managing hypertension and related conditions caused by an overactive sympathetic nervous system.

V-Wave Ltd. is a private company that develops percutaneous implantable therapeutic devices for patients suffering from chronic heart failure. Founded in 2009 and headquartered in Caesarea, Israel, with additional offices in the United States, V-Wave has created a proprietary interatrial shunt designed to alleviate symptoms associated with both preserved and reduced ejection fraction heart failure. This biocompatible implant regulates left atrial pressure, addressing a key factor in the deterioration of heart failure. The device aims to enhance patients' quality of life by reducing hospitalizations and improving exercise capacity. V-Wave's team consists of experienced engineers and medical scientists dedicated to advancing treatment options for individuals who continue to experience debilitating symptoms despite optimal medical care.

Corindus designs, manufactures, and commercializes remote robotic systems for interventional procedures. The company's products include CorPath, which enables physicians to perform catheterization procedures from a remote location away from the radiation zone. The company was formerly known as Navicath, Ltd. Corindus was founded in 2002 and is based in Waltham, Massachusetts.

CathWorks Ltd. is a medical technology company that specializes in enhancing percutaneous coronary intervention (PCI) therapy decisions through its advanced computational science platform. Founded in 2013 and headquartered in Kfar-Saba, Israel, with an additional office in the United States, the company has developed the CathWorks FFRangio, a non-invasive device that provides objective, multi-vessel physiologic measurements. This tool transforms coronary angiography from a subjective visual assessment into an objective decision-making framework based on fractional flow reserve (FFR) metrics. By utilizing sophisticated algorithms to process visual information, CathWorks aims to improve the efficiency of cath lab operations and support healthcare providers in making data-driven clinical decisions.

Trice Medical, Inc. is a company that specializes in developing orthopedic diagnostic devices incorporating camera-enabled and needle-based technologies. Founded in 2011 and based in Malvern, Pennsylvania, Trice Medical aims to enhance orthopedic diagnostics for patients, physicians, and payors by providing immediate, clear answers through its innovative solutions. By enabling micro-invasive procedures that are painless and cosmetically undetectable, the company's products facilitate office-based diagnostic and therapeutic applications. Trice Medical's technology integrates miniaturized optoelectronics, optimizing clinical services and addressing the shortcomings of traditional diagnostic modalities, thereby reducing false readings and overall healthcare costs.

Corindus designs, manufactures, and commercializes remote robotic systems for interventional procedures. The company's products include CorPath, which enables physicians to perform catheterization procedures from a remote location away from the radiation zone. The company was formerly known as Navicath, Ltd. Corindus was founded in 2002 and is based in Waltham, Massachusetts.

TransMedics Group Inc is a commercial-stage medical technology company focused on transforming organ transplant therapy for patients with end-stage organ failure. The company has developed the Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system designed to replicate near-physiologic conditions for donor organs outside the human body. This innovative system addresses the limitations associated with traditional cold storage organ preservation, enhancing clinical outcomes and increasing transplant volumes. By providing advanced technology and clinical service solutions, TransMedics aims to improve the overall effectiveness of heart and lung transplant procedures, thereby reducing learning curves for medical professionals involved in organ transplantation.

TransMedics Group Inc is a commercial-stage medical technology company focused on transforming organ transplant therapy for patients with end-stage organ failure. The company has developed the Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system designed to replicate near-physiologic conditions for donor organs outside the human body. This innovative system addresses the limitations associated with traditional cold storage organ preservation, enhancing clinical outcomes and increasing transplant volumes. By providing advanced technology and clinical service solutions, TransMedics aims to improve the overall effectiveness of heart and lung transplant procedures, thereby reducing learning curves for medical professionals involved in organ transplantation.

V-Wave Ltd. is a private company that develops percutaneous implantable therapeutic devices for patients suffering from chronic heart failure. Founded in 2009 and headquartered in Caesarea, Israel, with additional offices in the United States, V-Wave has created a proprietary interatrial shunt designed to alleviate symptoms associated with both preserved and reduced ejection fraction heart failure. This biocompatible implant regulates left atrial pressure, addressing a key factor in the deterioration of heart failure. The device aims to enhance patients' quality of life by reducing hospitalizations and improving exercise capacity. V-Wave's team consists of experienced engineers and medical scientists dedicated to advancing treatment options for individuals who continue to experience debilitating symptoms despite optimal medical care.

Kona Medical, Inc. is a medical technology company founded in 2009 and based in Issaquah, Washington. It specializes in the development of a non-invasive ultrasound-based therapy system aimed at treating hypertension, particularly in patients with drug-resistant hypertension. The company's flagship product, Surround Sound, utilizes ultrasound imaging to precisely guide the application of focused ultrasound energy for renal denervation, targeting the nerves connected to the kidneys to help regulate blood pressure. By offering a less invasive alternative to traditional treatments, Kona Medical seeks to address the health risks associated with high blood pressure while improving patient outcomes through advanced therapeutic techniques.

Aria CV, Inc. is a medical device company based in St. Paul, Minnesota, founded in 2010 by Drs. John Scandurra and Karl Vollmers. The company specializes in developing an implantable cardiovascular device aimed at treating pulmonary arterial hypertension (PAH). This innovative device is designed to reduce the workload on the right side of the heart, potentially enhancing both survival rates and the quality of life for patients suffering from this condition. Aria CV holds an exclusive license for certain patents from the University of Minnesota, reflecting its strong ties to academic research and innovation in the field of medical devices.

Trice Medical, Inc. is a company that specializes in developing orthopedic diagnostic devices incorporating camera-enabled and needle-based technologies. Founded in 2011 and based in Malvern, Pennsylvania, Trice Medical aims to enhance orthopedic diagnostics for patients, physicians, and payors by providing immediate, clear answers through its innovative solutions. By enabling micro-invasive procedures that are painless and cosmetically undetectable, the company's products facilitate office-based diagnostic and therapeutic applications. Trice Medical's technology integrates miniaturized optoelectronics, optimizing clinical services and addressing the shortcomings of traditional diagnostic modalities, thereby reducing false readings and overall healthcare costs.

Conventus Orthopaedics provides a range of orthopedic and sports medicine services. The physicians specialize in orthopedic surgery, reconstructive surgery, spine surgery, joint replacement, sports medicine, physical therapy, and operative care of fractures, arthritis, strains, sprains, and sports-related injuries. Conventus was formed by a team of medical professionals with the sole purpose of creating less invasive ways to treat challenging periarticular fractures. By leveraging advanced nitinol technology, the Conventus team has developed a platform technology that provides robust fixation and creates reliable repairs. The company was incorporated in 2009 and is based in Maple Grove, Minnesota.

VytronUS, Inc. specializes in the manufacture and marketing of cardiac medical devices aimed at treating cardiac arrhythmias. Founded in 2006 and located in Sunnyvale, California, the company focuses on leveraging ultrasound energy to enhance the imaging and therapeutic capabilities of its devices. These innovative products allow for precise non-contact energy delivery and facilitate the production of high-resolution maps of cardiac anatomy. By providing physicians with tools that enable visualization, precision, flexibility, and automation, VytronUS aims to improve the treatment of complex arrhythmias.

Domain Surgical is a medical device company that is creating energy-based surgical products for precise soft tissue cutting and coagulation. It creates energy-based equipment used in specialty surgical procedures. Its patent-pending technology produces surface-only tissue effects with energy that does not pass through the patient designed with the surgical staff in mind, for simple user-interface and training. The company manufactures and markets the FMwand Ferromagnetic Surgical System, a hemostatic dissection device that uses pure thermal energy to cut and coagulate soft tissue, without passing an electrical current through the patient. The FMwand imparts as little as 1/10th the amount of thermal injury compared to traditional electrosurgery devices. The FMwand provides fine dissection with a layer-by-layer precision that is unmatched by existing surgical technology.

Ablative Solutions, Inc. is a clinical-stage medical device company focused on developing innovative treatments for hypertension. Incorporated in 2011 and headquartered in San Jose, California, with an additional office in Kalamazoo, Michigan, the company manufactures the Peregrine System, an endovascular catheter designed for the minimally invasive delivery of diagnostic and therapeutic agents into the perivascular space surrounding peripheral blood vessels. This technology provides a safe and effective alternative to traditional surgical renal denervation, aiming to reduce blood pressure in patients with hypertension that is not well controlled. By using alcohol as a neurolytic agent, Ablative Solutions' infusion catheter may offer significant advantages over energy-based systems, making it a promising option for managing hypertension and related conditions caused by an overactive sympathetic nervous system.

Trice was founded to fundamentally improve orthopedic diagnostics and therapeutics by enabling instant and accurate office-based procedures. Our company is pioneering camera-enabled needle technologies that integrate miniaturized opto-electronics into well-designed clinical solutions. Our products will benefit Patients, Physicians and Payers by providing more immediate and definitive patient care, eliminating the false reads associated with current indirect modalities and significantly reducing cost to the healthcare system via existing reimbursement codes.

Angioslide, founded in 2005 by Eran Hirszowicz and Amos Nahir, is a privately-held medical device company. The company has developed a unique Embolic Capture Angioplasty™ (ECA) device family that combines standard balloon angioplasty with debris removal capabilities through its suction mechanism. Physicians using the PROTEUS™ device can now capture and remove embolic particles during angioplasty procedures.

Kona Medical, Inc. is a medical technology company founded in 2009 and based in Issaquah, Washington. It specializes in the development of a non-invasive ultrasound-based therapy system aimed at treating hypertension, particularly in patients with drug-resistant hypertension. The company's flagship product, Surround Sound, utilizes ultrasound imaging to precisely guide the application of focused ultrasound energy for renal denervation, targeting the nerves connected to the kidneys to help regulate blood pressure. By offering a less invasive alternative to traditional treatments, Kona Medical seeks to address the health risks associated with high blood pressure while improving patient outcomes through advanced therapeutic techniques.

Ablative Solutions, Inc. is a clinical-stage medical device company focused on developing innovative treatments for hypertension. Incorporated in 2011 and headquartered in San Jose, California, with an additional office in Kalamazoo, Michigan, the company manufactures the Peregrine System, an endovascular catheter designed for the minimally invasive delivery of diagnostic and therapeutic agents into the perivascular space surrounding peripheral blood vessels. This technology provides a safe and effective alternative to traditional surgical renal denervation, aiming to reduce blood pressure in patients with hypertension that is not well controlled. By using alcohol as a neurolytic agent, Ablative Solutions' infusion catheter may offer significant advantages over energy-based systems, making it a promising option for managing hypertension and related conditions caused by an overactive sympathetic nervous system.

Kona Medical, Inc. is a medical technology company founded in 2009 and based in Issaquah, Washington. It specializes in the development of a non-invasive ultrasound-based therapy system aimed at treating hypertension, particularly in patients with drug-resistant hypertension. The company's flagship product, Surround Sound, utilizes ultrasound imaging to precisely guide the application of focused ultrasound energy for renal denervation, targeting the nerves connected to the kidneys to help regulate blood pressure. By offering a less invasive alternative to traditional treatments, Kona Medical seeks to address the health risks associated with high blood pressure while improving patient outcomes through advanced therapeutic techniques.

CV Ingenuity, a Palo Alto, CA-based medical device company. CV Ingenuity Corp., a medical device company, develops devices for the treatment of vascular diseases to relieve vascular obstructions, inhibit restenosis, and allow natural vessel healing. It offers Drug Coated Balloon platform for the "Touch-and-Go" treatment of vascular disease. It was incorporated in 2008 and is based in Fremont, California. As of January 10, 2013, CV Ingenuity Corp. operates as a subsidiary of Covidien plc.

Ellipse Technologies is a privately-held medical device company based in California, specializing in the development of innovative implantable remote control technology for spinal and orthopedic applications. The company focuses on creating non-invasively adjustable implants designed to address a wide range of conditions, including spinal deformities and orthopedic trauma. Its flagship products include the MAGEC MAGnetic Expansion Control System, which employs a minimally-invasive method to correct spinal deformities through remote adjustment using an external magnetic field, and the PRECICE System, which utilizes adjustable intramedullary rods or bone plates to manage long-bone abnormalities resulting from fractures. Ellipse is dedicated to advancing treatment options in the fields of spinal and orthopedic medicine.

Reverse Medical is a commercial-stage medical device company dedicated to developing innovative solutions for revascularizing patients suffering from acute ischemic strokes. The company specializes in creating embolic protection systems aimed at treating neurovascular disorders, with a strong emphasis on endovascular management of acute stroke conditions. Through its advanced medical technologies, Reverse Medical seeks to improve patient outcomes and enhance the overall standard of care in the treatment of stroke.

Embrella Cardiovascular, Inc. develops a system to enhance embolic cerebral protection, enabling interventionalists to reduce the frequency of embolic strokes during cardiovascular procedures. Embrella Cardiovascular, Inc. is based in Malvern, Pennsylvania.

Revascular Therapeutics is a medical device company that develops solutions for the intravascular treatment of complex lesions and total occlusions. Revascular develops percutaneous medical devices to reopen occluded vessels.

SynergEyes®, Inc. was founded in 2001 with a recognized need for a hybrid contact lens that combined the superior visual acuity of a rigid gas permeable lens with the comfort of a soft contact lens. The revolutionary SynergEyes® hybrid contact lens allows you to enjoy the best of both worlds - a stable, high oxygen permeable rigid center that delivers consistent, crisp, clear vision while the outer skirt gives you all the all-day comfort of a soft lens.

Corindus designs, manufactures, and commercializes remote robotic systems for interventional procedures. The company's products include CorPath, which enables physicians to perform catheterization procedures from a remote location away from the radiation zone. The company was formerly known as Navicath, Ltd. Corindus was founded in 2002 and is based in Waltham, Massachusetts.

AorTx, Inc. develops device solutions for percutaneous replacement of the aortic valve in the United States. Its devices cover the procedural solution for heart valve therapy from the implant to delivery and deployment of the valve. AorTx, Inc. was formerly known as CardiacMD, Inc. The company is based in Redwood City, California. As of November 15, 2007, AorTx, Inc. operates as a subsidiary of Hansen Medical, Inc.

Avantis Medical Systems, Inc. is a medical device company founded to develop and manufacture catheter-based endoscopic devices. Based in Sunnyvale, California, the Company’s initial focus is on devices for use in detecting and treating cancers and other abnormalities of the gastrointestinal (GI) tract. The Avantis team has many decades of experience in the medical device industry. The Company is developing a number of innovative devices based on the convergent technologies of micro-chips and reinforced catheters.

Pynk is a wealth management platform that leverages Artificial Intelligence to harness the collective intelligence of its global crowd, which spans over 185 countries. By gathering predictions and forecasts on financial assets from its members, Pynk employs machine learning to analyze and interpret market trends, supporting more informed investment decisions. Founded in 2018 by entrepreneurs Seth Ward, Rupert Barksfield, and Mark Little, Pynk aims to democratize investment insights through its innovative 'Crowd Wisdom' system. The company has successfully raised $2 million in pre-seed and seed funding and continues to seek additional investment to further develop its platform. Pynk is also backed by prominent financial institutions in the UK, positioning itself to enhance the investing experience for both novice and seasoned investors.

Broncus Medical is a medical technology company specializing in the development of minimally-invasive devices for treating lung diseases, particularly emphysema. The company is known for its Exhale product line, which features the patented Airway Bypass technique, potentially being the first minimally-invasive procedure for homogeneous emphysema, a common form of the disease affecting many patients. Broncus is actively enrolling participants in its pivotal EASE Trial to evaluate this innovative treatment for severe homogeneous emphysema. In addition to its emphysema-focused efforts, Broncus operates within the interventional pulmonology sector, offering a range of products designed to enhance the diagnosis and treatment of lung conditions, including lung cancer and chronic obstructive pulmonary disease (COPD). The company is headquartered in Mountain View, California, with an international presence in Nyon, Switzerland.

Avantis Medical Systems, Inc. is a medical device company founded to develop and manufacture catheter-based endoscopic devices. Based in Sunnyvale, California, the Company’s initial focus is on devices for use in detecting and treating cancers and other abnormalities of the gastrointestinal (GI) tract. The Avantis team has many decades of experience in the medical device industry. The Company is developing a number of innovative devices based on the convergent technologies of micro-chips and reinforced catheters.